Display options
Cite
Eibl MM, Wolf HM. Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s). Folia Microbiol (Praha). 1995;40(4):360-6doi: 10.1007/BF02814744.
Eibl, M. M., & Wolf, H. M. (1995). Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s). Folia microbiologica, 40(4), 360-6. https://doi.org/10.1007/BF02814744
Eibl, M M, and Wolf, H M. "Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s)." Folia microbiologica vol. 40,4 (1995): 360-6. doi: https://doi.org/10.1007/BF02814744
Eibl MM, Wolf HM. Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s). Folia Microbiol (Praha). 1995;40(4):360-6. doi: 10.1007/BF02814744. PMID: 8763150.
Copy Download .nbib Format: NLM
Share it on

Folia Microbiol (Praha). 1995;40(4):360-6. doi: 10.1007/BF02814744.

Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s).

Folia microbiologica

M M Eibl, H M Wolf

Affiliations

  1. Institute of Immunology, University of Vienna.

PMID: 8763150 DOI: 10.1007/BF02814744

Abstract

Common variable immunodeficiency (CVID) comprises a heterogeneous group of patients with as yet undefined genetic defects. Patients with CVID have in common a decrease in the levels of one or more serum immunoglobulin isotypes and a severe defect in the production of specific antibodies. Typically, the patients suffer from recurrent infections of the upper and lower respiratory tract or the gastrointestinal tract. In consequence of these infections patients may develop severe organ damage, such as chronic pulmonary disease with bronchiectases, leading to pulmonary failure. Early diagnosis of CVID is important, as antibody deficiency can efficiently be treated by regular intravenous IgG (IVIG) substitution therapy. IVIG therapy prevents the occurrence of further acute infectious episodes and the development of long-term complications. The basic immunological defect(s) in patients with CVID are still unknown. There is currently no convincing evidence for an intrinsic B-cell defect in patients with CVID. A defect in T-cell activation due to impaired signal transduction upon T-cell receptor triggering has been described in a large subgroup of patients with CVID. Defective T-cell activation may lead to an impairment in cognate T-B-cell interaction due to impaired expression of CD40 ligand and/or abnormalities in the production T-cell-derived cytokines required for fully functional B-cell activation, proliferation and/or differentiation which could indeed explain the impairment in antibody production present in CVID patients.

References

  1. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1099-103 - PubMed
  2. Adv Pediatr Infect Dis. 1992;7:85-108 - PubMed
  3. BMJ. 1994 Feb 26;308(6928):581-5 - PubMed
  4. Nature. 1993 Feb 11;361(6412):541-3 - PubMed
  5. Immunol Rev. 1994 Apr;138:5-21 - PubMed
  6. Nature. 1993 Jan 21;361(6409):226-33 - PubMed
  7. Nature. 1994 Feb 3;367(6462):425-8 - PubMed
  8. Nature. 1977 Jul 14;268(5616):154-6 - PubMed
  9. J Immunol. 1990 May 15;144(10):3762-9 - PubMed
  10. Clin Exp Immunol. 1990 Sep;81(3):412-6 - PubMed
  11. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  12. Cell. 1993 Jan 29;72(2):279-90 - PubMed
  13. Clin Exp Immunol. 1992 Oct;90(1):25-30 - PubMed
  14. J Clin Immunol. 1989 Jan;9(1):22-33 - PubMed
  15. Clin Exp Immunol. 1994 Apr;96(1):48-53 - PubMed
  16. Aust N Z J Med. 1974 Jun;4(3):243-6 - PubMed
  17. J Immunol. 1994 Jun 15;152(12):5957-68 - PubMed
  18. Br J Haematol. 1994 Nov;88(3):520-6 - PubMed
  19. JAMA. 1990 Dec 26;264(24):3189-93 - PubMed
  20. Immunodefic Rev. 1989;1 Suppl:1-42 - PubMed
  21. Ann Intern Med. 1972 Nov;77(5):746-50 - PubMed
  22. Am J Med. 1976 Aug;61(2):221-37 - PubMed
  23. Birth Defects Orig Artic Ser. 1975;11(1):199-207 - PubMed
  24. Int Immunol. 1993 Jul;5(7):769-73 - PubMed
  25. Lancet. 1985 Feb 2;1(8423):263-6 - PubMed
  26. J Clin Immunol. 1981 Apr;1(2):113-8 - PubMed
  27. Blood. 1990 Nov 15;76(10):2046-51 - PubMed
  28. Scand J Immunol. 1995 Mar;41(3):215-9 - PubMed
  29. Blood. 1994 Dec 15;84(12):4234-41 - PubMed
  30. Science. 1993 Feb 12;259(5097):990-3 - PubMed
  31. Clin Immunol Immunopathol. 1987 Aug;44(2):206-18 - PubMed
  32. Br Med J. 1976 May 29;1(6021):1314-6 - PubMed
  33. Cell. 1993 Jan 29;72(2):291-300 - PubMed
  34. J Clin Invest. 1973 Dec;52(12):3180-9 - PubMed
  35. Nature. 1993 Feb 11;361(6412):539-41 - PubMed
  36. Lancet. 1974 Sep 14;2(7881):609-13 - PubMed
  37. J Lab Clin Med. 1957 Mar;49(3):343-57 - PubMed
  38. Ann Intern Med. 1993 May 1;118(9):720-30 - PubMed
  39. J Clin Immunol. 1987 Jul;7(4):294-9 - PubMed
  40. Am J Med. 1969 Sep;47(3):340-50 - PubMed
  41. Clin Exp Immunol. 1989 Dec;78(3):334-40 - PubMed
  42. J Clin Invest. 1993 Sep;92(3):1282-7 - PubMed
  43. J Allergy Clin Immunol. 1993 Aug;92(2):340-52 - PubMed
  44. Ann Intern Med. 1984 Apr;100(4):522-4 - PubMed
  45. Lancet. 1972 May 27;1(7761):1149-52 - PubMed
  46. Clin Exp Immunol. 1994 Feb;95(2):209-14 - PubMed
  47. Ann Intern Med. 1971 Jun;74(6):903-10 - PubMed

Substances

MeSH terms

Publication Types